Please ensure Javascript is enabled for purposes of website accessibility

Why Cassava Sciences Stock Is Skyrocketing Today

By Keith Speights - Updated Mar 17, 2021 at 3:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst expects shares to more than double over the next 12 months.

What happened

Shares of Cassava Sciences (SAVA 5.57%) were 19.2% higher as of 3:20 p.m. EDT on Wednesday. The big jump came after Jones Trading analyst Soumit Roy initiated coverage on the stock with a buy rating. Roy set a one-year price target of $110, a 111% premium over Cassava's closing price on Tuesday.

So what

It's not a good idea to buy a biotech stock just because an analyst is bullish about it. But understanding what an analyst likes about the stock can be helpful.

Form with "Alzheimer's Disease" printed at the top with a pen, syringes, X-ray images, and stethoscope on top of the form

Image source: Getty Images.

In this case, Jones Trading's Roy is optimistic about the prospects for Cassava's experimental Alzheimer's disease drug simufilam. The company met in February with the Food and Drug Administration about advancing the drug candidate into a pivotal late-stage clinical study.

Success for experimental Alzheimer's disease drugs has been hard to achieve in the past. Several once-promising candidates ultimately flopped in late-stage testing. Cassava CEO Remi Barbier stated last month that the company "believe[s] the underlying science [for simufilam] is solid." If the biotech's pivotal studies go well, its stock will likely be worth a lot more than even the significantly higher target price set by Jones Trading.

Now what

Cassava plans to start the first of its two late-stage studies of simufilam in the third quarter of this year. That study will evaluate the disease-modifying effects of the drug in treating Alzheimer's. The biotech expects to kick off the second pivotal study -- to evaluate symptomatic improvement in patients who receive simufilam -- in the fourth quarter.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cassava Sciences, Inc. Stock Quote
Cassava Sciences, Inc.
SAVA
$26.92 (5.57%) $1.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.